Image_1_Prevalence of Pure Red Cell Aplasia Following Major ABO-Incompatible Hematopoietic Stem Cell Transplantation.tif
Pure red cell aplasia (PRCA) is one of the important complications in major ABO-incompatible allogeneic hematopoietic stem cell transplantation (HSCT). The established pathogenic factor of PRCA is the persistence of high anti-donor isohemagglutinins. As previously verified, the conditioning regimen and donor type were the factors associated with the development of PRCA in the small-sized studies. Currently, the prevalence, risk factors, and prognosis of PRCA are still worth studying to provide evidence.
MethodsWe conducted a prospective nested case-control study to determine the prevalence, donor-related factors, and the outcomes of PRCA following major ABO-incompatible transplantation. A total of 469 patients who underwent ABO-incompatible grafts were observed.
ResultsNone of the patients were diagnosed with PRCA with minor or bidirectional ABO-incompatible HSCT. Thirteen of the187 patients (7%; 95% confidence interval [CI], 3.9%–11.9%) developed PRCA following major ABO-incompatible HSCT. Eleven of the 13 patients with PRCA recovered entirely. Donor type was an independent factor associated with post-HSCT PRCA (odds ratio [OR]=0.030; 95% CI, 0.003–0.321; P=0.004). The cumulative incidence rates of post-HSCT PRCA in the context of major ABO-incompatible HSCT were 0.8%, 13.1%, and 27.2% for the haploidentical donor (HID), unrelated donor, and matched related donor, respectively. No significant influence of PRCA on transplantation outcomes was observed.
In conclusion, post-HSCT PRCA is a rare and less threatening complication in major ABO-incompatible HSCT. The majority of patients with PRCA could recover. Additionally, HIDs for recipients may have a low risk of post-HSCT PRCA. This trial was registered at www.chictr.org.cn (#ChiCTR2000041412).
History
References
- https://doi.org//10.1016/j.bbmt.2013.03.018
- https://doi.org//10.1038/s41409-019-0496-2
- https://doi.org//10.1002/ajh.24771
- https://doi.org//10.3324/haematol.2016.160804
- https://doi.org//10.2450/2017.0322-16
- https://doi.org//10.1182/blood.V98.6.1687
- https://doi.org//10.1111/bjh.12210
- https://doi.org//10.1038/sj.bmt.1702121
- https://doi.org//10.3324/haematol.13356
- https://doi.org//10.1111/j.1365-2141.2005.05364.x
- https://doi.org//10.1007/s00277-007-0304-8
- https://doi.org//10.1182/blood.V75.1.290.290
- https://doi.org//10.1046/j.1365-2141.2003.04128.x
- https://doi.org//10.1097/00007890-200109270-00010
- https://doi.org//10.1080/10245330601111540
- https://doi.org//10.1111/j.1537-2995.2005.04236.x
- https://doi.org//10.1111/j.1423-0410.1992.tb01194.x
- https://doi.org//10.1111/j.1423-0410.1967.tb03362.x
- https://doi.org//10.1016/0165-2478(93)90185-5
- https://doi.org//10.1182/blood.V96.3.1150
- https://doi.org//10.1038/s41409-020-01124-6
- https://doi.org//10.1182/blood-2014-04-571570
- https://doi.org//10.1111/j.1365-2141.2008.07216.x
- https://doi.org//10.1182/blood-2014-01-552984
- https://doi.org//10.1111/bjh.17463
- https://doi.org//10.1182/blood-2018-99-115075
- https://doi.org//10.1097/00001813-199512000-00010
- https://doi.org//10.1038/s41409-020-0939-9
- https://doi.org//10.3109/10428199309148522
- https://doi.org//10.1016/j.bbmt.2013.04.004
- https://doi.org//10.1046/j.1537-2995.2000.40050543.x
- https://doi.org//10.1007/BF00336406
- https://doi.org//10.1111/trf.13269
- https://doi.org//10.1002/jca.21553
- https://doi.org//10.1056/NEJMoa1807438
- https://doi.org//10.1038/s41409-021-01507-3
- https://doi.org//10.1016/j.bbmt.2018.04.022
- https://doi.org//10.1038/sj.bmt.1703668
Usage metrics
Read the peer-reviewed publication
Categories
- Transplantation Immunology
- Tumour Immunology
- Immunology not elsewhere classified
- Immunology
- Veterinary Immunology
- Animal Immunology
- Genetic Immunology
- Applied Immunology (incl. Antibody Engineering, Xenotransplantation and T-cell Therapies)
- Autoimmunity
- Cellular Immunology
- Humoural Immunology and Immunochemistry
- Immunogenetics (incl. Genetic Immunology)
- Innate Immunity